Cardiome Pharma has announced submission of the Brinavess reimbursement dossier to Belgium’s national compulsory health care and benefits insurance authority, The National Institute for Health and Disability Insurance (Institut National d’Assurance Maladie Invalidité or INAMI).
“We are pleased to have submitted the application for Brinavess reimbursement and potentially could have the drug available to physicians in Belgium as an important new option to treat patients with recent-onset atrial fibrillation,” says Karim Lalji, Cardiome’s chief commercial officer. “Cardiome is committed to making Brinavess available in all of the key European markets. We believe the pharmacoeconomic case for Brinavess presented to INAMI puts us one step closer towards achieving this goal.”
